53.83
+1.14(+2.16%)
Currency In USD
| Previous Close | 52.69 |
| Open | 52.77 |
| Day High | 53.97 |
| Day Low | 52.33 |
| 52-Week High | 118.21 |
| 52-Week Low | 47.25 |
| Volume | 704,917 |
| Average Volume | 1.68M |
| Market Cap | 3.66B |
| PE | 14.32 |
| EPS | 3.76 |
| Moving Average 50 Days | 56.75 |
| Moving Average 200 Days | 81.09 |
| Change | 1.14 |
If you invested $1000 in Lantheus Holdings, Inc. (LNTH) 10 years ago, it would be worth $14,470.43 as of October 04, 2025 at a share price of $53.83. Whereas If you bought $1000 worth of Lantheus Holdings, Inc. (LNTH) shares 5 years ago, it would be worth $3,958.09 as of October 04, 2025 at a share price of $53.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan
GlobeNewswire Inc.
Sep 24, 2025 5:00 AM GMT
BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) and GE HealthCare (NASDAQ: GEHC) today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commer
Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire Inc.
Sep 02, 2025 12:30 PM GMT
BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient out
Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent
GlobeNewswire Inc.
Aug 06, 2025 10:45 AM GMT
Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resiliencePDUFA date set for March 6, 2026 BEDFORD, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: